Description
Phasostabil Pharmacodynamics
The mechanism of action of acetylsalicylic acid (ASA) is based on irreversible inhibition of cyclooxygenase (COX-1), which blocks the synthesis of thromboxane A2 and inhibits platelet aggregation. It is believed that ASA has other mechanisms to inhibit platelet aggregation, which expands the field of its use in various vascular diseases. ASA also has anti-inflammatory, analgesic, and antipyretic effects. The anti-inflammatory effect is associated with a decrease in blood flow due to inhibition of prostaglandin E2 synthesis.
Magnesium hydroxide, which is part of the drug Fazostabil, has an antacid effect and protects the mucous membrane of the gastrointestinal tract from the effects of ASA.
Indications
– Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure in the presence of risk factors (e.g. diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age);
– Prevention of recurrent myocardial infarction and blood vessel thrombosis;
– Prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty);
– unstable angina pectoris.
Contraindications
– Hypersensitivity to ASA, excipients of the drug and other nonsteroidal anti-inflammatory drugs (NSAIDs);
– cerebral hemorrhage;
– susceptibility to bleeding (vitamin K insufficiency, thrombocytopenia, hemorrhagic diathesis);
– chronic heart failure functional class III-IV according to NYHA classification;
– Bronchial asthma induced by taking salicylates and NSAIDs;
– complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis, and intolerance to ASA or other NSAIDs, including cyclooxygenase-2 (COX-2) inhibitors (including history);
– gastrointestinal erosive and ulcerative lesions (acute phase);
– gastrointestinal bleeding;
– severe renal insufficiency (creatinine clearance (CK) less than 30 ml/min);
– hepatic insufficiency (class B and C according to the Child-Pugh classification);
– pregnancy (I and III trimesters), breastfeeding;
– Glucose-6-phosphate dehydrogenase deficiency;
– concomitant use with methotrexate (more than 15 mg per week);
– Childhood under 18 years of age.
Dosage and administration
- Orally, film-coated tablets of Fasostabil are swallowed whole with water.
- The drug Fasostabil is suitable for long-term treatment. Duration of treatment is determined by the physician.
- – Primary prevention of cardiovascular diseases, such as thrombosis and acute cardiac insufficiency in the presence of risk factors (e.g. diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age)
- 1 tablet of Fazostabil, containing ASK in a dose of 150 mg the first day, and then 1 tablet containing ASK in a dose of 75 mg once a day.
- – Prevention of recurrent myocardial infarction and blood vessel thrombosis
- 1 tablet of Fazostabil, containing ASA, in a dose of 75-150 mg once daily.
- – Prophylaxis of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty).
- 1 tablet of the drug Fazostabil, containing ASA at a dose of 75-150 mg once a day.
- – Unstable angina pectoris
- 1 tablet of Fasostabil with ASA in a dose of 75-150 mg once daily.
- If another dose of Fasostabil is missed, take the missed dose as soon as the patient remembers it. To avoid doubling the dose, do not take the missed tablet if the time for the next dose is approaching.
- No peculiarities of action have been observed when first taking or cancelling the drug.
